Navigation Links
OncoGenex increases economic interest in lead cancer drug OGX-011
Date:7/3/2008

VANCOUVER, July 3 /PRNewswire/ - OncoGenex Technologies Inc. and Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that the companies have amended their agreement and OncoGenex has elected to independently develop its lead cancer drug OGX-011. Under the amended agreement, OncoGenex is solely responsible for all future development activities, costs and partnering decisions related to OGX-011. Isis will no longer be responsible for funding 35% of development costs, will receive single digit royalties on future revenues of OGX-011, and will receive a portion of license fees and milestone payments received by OncoGenex from any future partner. There were no upfront payments associated with this amended agreement.

"This amendment allows us to increase our economic interest in OGX-011 as we advance the development of OGX-011 while also increasing our flexibility to further develop this product candidate," said Scott Cormack, President and CEO of OncoGenex. "In addition, we believe this new arrangement facilitates future partnering discussions since potential development and commercialization partners need only deal with one party."

"This amended agreement with OncoGenex is consistent with our strategy to remain focused on discovering and developing drugs and licensing prior to large Phase 3 trials. This has enabled us to continue to benefit from the successes of antisense drugs through a growing annuity of licensing fees, milestones and royalty payments with many focused partners," said B. Lynne Parshall, COO and CFO of Isis. "We believe that clinical results to date have established OGX-011 as one of many promising antisense drugs and OncoGenex is now ideally situated to lead the final stages of development of OGX-011 whi
'/>"/>

SOURCE OncoGenex Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
5. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
6. Chambersburg Hospital Streamlines Pharmacy Process and Increases Patient Safety With Omnicell WorkflowRx 5.0
7. Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk
8. Double Resonance Probe for Liquid State NMR Applications From Varian, Inc. Increases Productivity for Routine Analyses
9. New Dual Cold Probe From Varian, Inc. Increases Sensitivity and Reduces Analysis Times for 13C NMR Experiments
10. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
11. Hyaluron Contract Manufacturing Named a 2007 Economic Impact Award Finalist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Communications, a leading provider of strategic communications services to corporations and ... the United States and Europe ... JD, is returning to the firm,s Washington, D.C. ... more than two years of service as Associate Commissioner for the ...
(Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an ... products to serve the wound care market. , Free ... Alliqua was restructured with a seasoned management team and ...
(Date:1/14/2014)... and BETHESDA, Md. , ... joining together with two institutes from the National Institutes ... tools for bringing safer, more effective treatments to patients ... National Center for Advancing Translational Sciences (NCATS) and the ...
(Date:1/14/2014)... In recent years, growing suspicion about the pharmaceutical ... and promotion has led to unprecedented levels of public ... about the insidious impact of commercialization of research, has ... the world’s biggest pharmas for illegal marketing activities, allegations ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... In Vitro and In Vivo Data Show AEZS-126 as ... CancerQUEBEC CITY, April 21 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. ... biopharmaceutical company focused on endocrine therapy and oncology, today ... clinical intervention of the PI3K/ Akt pathway in human ...
... HUBBARD, Ohio, April 21 NanoLogix, Inc. (OTC: NNLX) ... square foot manufacturing facility at its headquarters in Hubbard, ... vault, and shipping and receiving area to be used ... revolutionary new BNP(TM) kits provide accelerated detection of bacteria ...
... Data Selected for Presentation Highlights Anti-Tumor effects of ... Inc. (Nasdaq: KERX ) today announced ... effects of KRX-0401 (perifosine), the company,s lead anti-cancer ... (AACR) Annual Meeting, being held in Denver, Colorado. ...
Cached Biology Technology:AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting 2AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting 3NanoLogix Begins Construction of Production Facility for Medical Test Kits 2NanoLogix Begins Construction of Production Facility for Medical Test Kits 3Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research 2Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research 3Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research 4
(Date:4/22/2014)... new secret to get your child to behave at the ... new Cornell study published in Eating Behaviors , found ... to bite with their front teeth such as drumsticks, whole ... than when these foods had been cut. "They were ... toward other kids," said Brian Wansink, Professor and Director of ...
(Date:4/22/2014)... from the Florida campus of The Scripps Research Institute ... critical but previously unknown role in learning and memory ... role for a protein known as RGS7, was published ... a publisher supported by the Howard Hughes Medical Institute, ... "This is a critical building block that regulates a ...
(Date:4/22/2014)... Scientists at the University of Massachusetts Amherst and the ... week report that they have discovered a new genus ... the Negro River in the Amazonia State of Brazil. ... Adlia Nogueira and Jos Antnio Alves-Gomes of INPA, describe ... the journal Proceedings of the Natural Sciences of ...
Breaking Biology News(10 mins):Biting vs. chewing 2Scientists identify critical new protein complex involved in learning and memory 2New electric fish genus and species discovered in Brazil's Rio Negro 2
... Yang Wang is known for conducting complex research using highly ... spent days hiking through the remote outback of Tibet and ... the name of scientific discovery. Because of that unique ... a team of researchers that uncovered the oldest prehistoric woolly ...
... found in the oceans and belong to the group SAR11. ... an explanation for their success and at the same time ... their analysis they have also identified a rare and hitherto ... findings were published in two articles in the journals ...
... D.C. The American Association for Cancer Research will ... Cancer Health Disparities from Sept. 18-21, 2011, in the ... This conference will bring together scientists, survivors, doctors and ... epidemiology and treatment methods to better meet the needs ...
Cached Biology News:A wild and woolly discovery: FSU scientist's Tibetan expedition ends with prehistoric find 2A wild and woolly discovery: FSU scientist's Tibetan expedition ends with prehistoric find 3Unknown ocean bacteria create entirely new theories 2AACR to host conference on the science of cancer health disparities 2
...
... The Thermo Labsystems Wellmix is a high-quality ... time settings. The shaking speed is adjustable ... frequency, high speed and a small orbit ... The shaking time is quick and easy ...
Mouse monoclonal [AZ24] to Polo like kinase ( Abpromise for all tested applications)....
... together two mature, well-understood technologies: grating-based ... This combination produces a sensitive and ... of molecular binding events without the ... capture molecules are immobilized on the ...
Biology Products: